KRAS mutation screening

What is KRAS?

The KRAS gene makes the KRAS protein, which is involved in cell signaling pathways, cell growth, and apoptosis (natural cell death). When KRAS is mutated, it would lead to cancer.

How do mutations in KRAS relate to cancer?

KRAS mutations are common in lung, and colorectal cancers. They are activating mutations that result in uncontrolled cell growth. Ultimately it becomes cancer.

Why is detecting KRAS important?

Using anti-EGFR drugs is the most common targeted therapy approach nowadays to treat cancer. However, recent data shows that anti-EGFR therapy is unlikely to be beneficial in tumors with any KRAS mutations. Finding out these KRAS mutations is important in making decisions and predicting responses for targeted-therapies and/or other treatments specific for the patient tested.

Who should consider this test?

Patients who are suffering from non-small cell lung cancer (NSCLC) and colorectal cancer (CRC); or patients who have received targeted therapy and failed to show signs of recovery are both advised to perform this test.

Test Specifications

Test Code
Methodology
Specimen Requirements
Turnaround Time
OKR
Real-time PCR (RT-PCR)
4 FFPE unstained sections (6 µm) with at least 20% tumor content
3 days

What should I do if my test results are positive?

Please consult your physicians for professional advices.

How to get started

Our tests must be ordered by a doctor. Ask your doctor if a Mygenia test is right for you. We can help you find a doctor if you don’t have one.

I have a doctor
References
  1. http://kras.eqascheme.org/info/public/eqa/index.xhtml
  2. http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=652256